BIO
Bio-Rad Laboratories, Inc.
Stock
$369.14+13.57 (+3.82%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B | $2.5B | $2.3B | $2.3B | $2.2B | $2.1B | $2.0B | $2.2B | $2.1B | $2.1B | $2.1B | $1.9B | $1.8B | $1.8B |
| Cost of revenue | $1.2B | $1.2B | $1.2B | $1.2B | $1.2B | $1.3B | $1.1B | $1.1B | $1.1B | $972M | $930M | $898M | $997M | $954M | $914M | $895M | $836M | $784M | $802M |
| Gross profit | $1.3B | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B | $1.4B | $1.3B | $1.2B | $1.2B | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $1,000M | $963M |
| R&D | $266M | $276M | $296M | $247M | $257M | $261M | $218M | $203M | $199M | $250M | $206M | $193M | $220M | $211M | $209M | $178M | $172M | $164M | $160M |
| SG&A | $852M | $844M | $814M | $842M | $828M | $877M | $799M | $825M | $835M | $807M | $815M | $762M | $808M | $798M | $682M | $696M | $635M | $601M | $591M |
| Other operating expenses | $173M | $173M | — | — | — | — | — | — | $293M | $12M | $62M | — | — | — | — | — | — | $3.8M | $29M |
| Operating income | $53M | $47M | $269M | $338M | $483M | $500M | $421M | $230M | −$103M | $119M | $56M | $167M | $150M | $169M | $264M | $305M | $284M | $231M | $183M |
| Non-operating income | $297M | $948M | −$2.6B | −$1.2B | −$5.2B | $4.9B | $4.5B | $2.0B | $616M | −$21M | −$14M | −$21M | −$18M | −$57M | −$34M | −$59M | −$64M | −$45M | −$40M |
| Pretax income | $350M | $996M | −$2.3B | −$850M | −$4.7B | $5.4B | $4.9B | $2.3B | $513M | $98M | $42M | $146M | $132M | $112M | $230M | $246M | $220M | $186M | $143M |
| Taxes | $128M | $236M | −$498M | −$213M | −$1.1B | $1.2B | $1.1B | $502M | $147M | −$24M | $16M | $37M | $43M | $35M | $64M | $67M | $35M | $41M | $53M |
| Net income | $222M | $760M | −$1.8B | −$637M | −$3.6B | $4.3B | $3.8B | $1.8B | $366M | $122M | $26M | $109M | $89M | $78M | $165M | $179M | $185M | $145M | $90M |
| Diluted EPS | $8.25 | $27.85 | −$65.36 | −$21.82 | −$121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 | $3.71 | $3.05 | $2.69 | $5.78 | $6.29 | $6.59 | $5.20 | $3.24 |
| Diluted shares | — | 27.3M | 28.2M | 29.2M | 29.8M | 30.2M | 30.2M | 30.2M | 30.2M | 30.0M | 29.6M | 29.4M | 29.1M | 28.9M | 28.6M | 28.5M | 28.2M | 27.8M | 27.6M |
| Revenue growth | — | +0.7% | −3.9% | −4.7% | −4.1% | +14.8% | +10.1% | +1.0% | +6.0% | +4.4% | +2.4% | −7.2% | +2.0% | +3.1% | −0.2% | +7.6% | +8.0% | +1.1% | — |
| Gross margin | 51.9% | 51.9% | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% | 54.4% | 53.4% | 55.0% | 55.0% | 55.5% | 54.2% | 55.3% | 55.8% | 56.9% | 56.6% | 56.0% | 54.6% |
| Operating margin | 2.1% | 1.8% | 10.5% | 12.6% | 17.2% | 17.1% | 16.6% | 9.9% | −4.5% | 5.5% | 2.7% | 8.3% | 6.9% | 7.9% | 12.8% | 14.7% | 14.7% | 12.9% | 10.4% |
| Net margin | 8.6% | 29.4% | −71.9% | −23.9% | −129.5% | 145.6% | 149.8% | 76.1% | 16.0% | 5.7% | 1.3% | 5.4% | 4.1% | 3.6% | 8.0% | 8.6% | 9.6% | 8.1% | 5.1% |